China Stops Sales Of OTC Pediatric Drugs Containing Amantadine
This article was originally published in PharmAsia News
China’s State FDA has recently forbidden the use of three top-selling OTC pediatric compounds containing amantadine for infants under the age of 1 for safety and efficacy reasons.
You may also be interested in...
With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.
AZ and the EU are at loggerheads over supplies of the COVID-19 vaccine. On top of that, its marketing authorization will present dilemmas.
The European Medicines Agency is expected to decide soon whether Amarin’s fish oil pill, Vascepa, should win pan-EU marketing approval for reducing cardiovascular risk.